When ERBB2 (HER2) is amplified or mutated, it becomes activated in a ligand-independent manner, driving activation of downstream pathways controlling the migration, proliferation, survival, and differentiation of cancer cells (1). The gene discussed is ERBB2; the disease is cancer.